Cargando…

Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid

BACKGROUND: Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder. Biomarkers that can help monitor the progression of PD or response to disease-modifying agents will be invaluable in making appropriate therapeutic decisions. Further, biomarkers that could be used to disti...

Descripción completa

Detalles Bibliográficos
Autores principales: Na, Chan Hyun, Sathe, Gajanan, Rosenthal, Liana S., Moghekar, Abhay R., Dawson, Valina L., Dawson, Ted M., Pandey, Akhilesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197159/
https://www.ncbi.nlm.nih.gov/pubmed/32390785
http://dx.doi.org/10.1186/s12014-020-09277-8
_version_ 1783528826167361536
author Na, Chan Hyun
Sathe, Gajanan
Rosenthal, Liana S.
Moghekar, Abhay R.
Dawson, Valina L.
Dawson, Ted M.
Pandey, Akhilesh
author_facet Na, Chan Hyun
Sathe, Gajanan
Rosenthal, Liana S.
Moghekar, Abhay R.
Dawson, Valina L.
Dawson, Ted M.
Pandey, Akhilesh
author_sort Na, Chan Hyun
collection PubMed
description BACKGROUND: Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder. Biomarkers that can help monitor the progression of PD or response to disease-modifying agents will be invaluable in making appropriate therapeutic decisions. Further, biomarkers that could be used to distinguish PD from other related disorders with PD-like symptoms will be useful for accurate diagnosis and treatment. C-Abl tyrosine kinase is activated in PD resulting in increased phosphorylation of the tyrosine residue at position 39 (Y39) of α-synuclein (α-syn) (pY39 α-syn), which contributes to the death of dopaminergic neurons. Because pY39 α-syn may be pathogenic, monitoring pY39 α-syn could allow us to diagnose presymptomatic PD and help monitor disease progression and response to treatment. We sought to investigate if increased phosphorylation of pY39 α-syn can be detected in the cerebrospinal fluid (CSF) of PD patients by targeted mass spectrometry. METHODS: Here, we report a two-step enrichment method in which phosphotyrosine peptides were first enriched with an anti-phosphotyrosine antibody followed by a second round of enrichment by titanium dioxide (TiO(2)) beads to detect EGVLpYVGSK sequence derived from tyrosine 39 region of α- and β-synuclein (αβ-syn). Accurate quantification was achieved by adding a synthetic heavy version of pY39 αβ-syn peptide before enzymatic digestion. RESULTS: Using the developed enrichment methods and optimized parallel reaction monitoring (PRM) assays, we detected pY39 αβ-syn peptide in human CSF and demonstrated that the ratio of pY39 αβ-syn to Y39 αβ-syn was significantly increased in the CSF of patients with PD. CONCLUSIONS: We anticipate that this optimized two-step enrichment-based PRM detection method will help monitor c-Abl activation in PD patients and can also be used to quantify other phosphotyrosine peptides of low abundance in biological samples.
format Online
Article
Text
id pubmed-7197159
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71971592020-05-08 Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid Na, Chan Hyun Sathe, Gajanan Rosenthal, Liana S. Moghekar, Abhay R. Dawson, Valina L. Dawson, Ted M. Pandey, Akhilesh Clin Proteomics Research BACKGROUND: Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder. Biomarkers that can help monitor the progression of PD or response to disease-modifying agents will be invaluable in making appropriate therapeutic decisions. Further, biomarkers that could be used to distinguish PD from other related disorders with PD-like symptoms will be useful for accurate diagnosis and treatment. C-Abl tyrosine kinase is activated in PD resulting in increased phosphorylation of the tyrosine residue at position 39 (Y39) of α-synuclein (α-syn) (pY39 α-syn), which contributes to the death of dopaminergic neurons. Because pY39 α-syn may be pathogenic, monitoring pY39 α-syn could allow us to diagnose presymptomatic PD and help monitor disease progression and response to treatment. We sought to investigate if increased phosphorylation of pY39 α-syn can be detected in the cerebrospinal fluid (CSF) of PD patients by targeted mass spectrometry. METHODS: Here, we report a two-step enrichment method in which phosphotyrosine peptides were first enriched with an anti-phosphotyrosine antibody followed by a second round of enrichment by titanium dioxide (TiO(2)) beads to detect EGVLpYVGSK sequence derived from tyrosine 39 region of α- and β-synuclein (αβ-syn). Accurate quantification was achieved by adding a synthetic heavy version of pY39 αβ-syn peptide before enzymatic digestion. RESULTS: Using the developed enrichment methods and optimized parallel reaction monitoring (PRM) assays, we detected pY39 αβ-syn peptide in human CSF and demonstrated that the ratio of pY39 αβ-syn to Y39 αβ-syn was significantly increased in the CSF of patients with PD. CONCLUSIONS: We anticipate that this optimized two-step enrichment-based PRM detection method will help monitor c-Abl activation in PD patients and can also be used to quantify other phosphotyrosine peptides of low abundance in biological samples. BioMed Central 2020-05-04 /pmc/articles/PMC7197159/ /pubmed/32390785 http://dx.doi.org/10.1186/s12014-020-09277-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Na, Chan Hyun
Sathe, Gajanan
Rosenthal, Liana S.
Moghekar, Abhay R.
Dawson, Valina L.
Dawson, Ted M.
Pandey, Akhilesh
Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid
title Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid
title_full Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid
title_fullStr Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid
title_full_unstemmed Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid
title_short Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid
title_sort development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197159/
https://www.ncbi.nlm.nih.gov/pubmed/32390785
http://dx.doi.org/10.1186/s12014-020-09277-8
work_keys_str_mv AT nachanhyun developmentofanovelmethodforthequantificationoftyrosine39phosphorylatedaandbsynucleininhumancerebrospinalfluid
AT sathegajanan developmentofanovelmethodforthequantificationoftyrosine39phosphorylatedaandbsynucleininhumancerebrospinalfluid
AT rosenthallianas developmentofanovelmethodforthequantificationoftyrosine39phosphorylatedaandbsynucleininhumancerebrospinalfluid
AT moghekarabhayr developmentofanovelmethodforthequantificationoftyrosine39phosphorylatedaandbsynucleininhumancerebrospinalfluid
AT dawsonvalinal developmentofanovelmethodforthequantificationoftyrosine39phosphorylatedaandbsynucleininhumancerebrospinalfluid
AT dawsontedm developmentofanovelmethodforthequantificationoftyrosine39phosphorylatedaandbsynucleininhumancerebrospinalfluid
AT pandeyakhilesh developmentofanovelmethodforthequantificationoftyrosine39phosphorylatedaandbsynucleininhumancerebrospinalfluid